Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy

26 Jun 2017

Abstract excerpt

Abstract Next-generation sequencing to detect circulating tumor DNA is a minimally invasive method for tumor genotyping and monitoring therapeutic response. The majority of studies have focused on detecting circulating tumor DNA from patients with metastatic disease. Herein, we tested whether circulating tumor DNA could be used as a biomarker to predict relapse in triple-negative breast cancer patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Genomics and Diagnostics
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28685160
DOI: 10.1038/s41523-017-0028-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapyPMID 28685160Read ↗

Circulating tumor DNA as a predictive marker of recurrence for patients with stage II-III breast cancer treated with neoadjuvant therapySemantic proximity Read ↗

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survivalSemantic proximity Read ↗

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.Semantic proximity Read ↗

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.Semantic proximity Read ↗

Prognostic value of circulating tumor DNA mutation panels to predict early recurrence and survival outcomes in early-stage breast cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.Semantic proximity Read ↗

Serial Circulating Tumor DNA Identification Associated with the Efficacy and Prognosis of Neoadjuvant Chemotherapy in Breast CancerSemantic proximity Read ↗

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.Semantic proximity Read ↗

Detection of residual disease after neoadjuvant therapy in breast cancer using personalized circulating tumor DNA analysisSemantic proximity Read ↗

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.Semantic proximity Read ↗

Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.Semantic proximity Read ↗

Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.